MedTrace Logo

Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers

NCT05099549 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2024-03-01

No results posted yet for this study

Summary

This is an open-label, multi-center study to evaluate the safety, tolerability, and anti-tumor activity of SNK01 in combination with AFM24 in subjects with advanced or metastatic EGFR-expressing cancers.

Conditions

  • Squamous Cell Carcinoma of Head and Neck
  • Carcinoma, Non-Small-Cell Lung
  • Colorectal Neoplasms
  • Advanced Solid Tumor
  • Refractory Tumor
  • Metastatic Tumor

Interventions

DRUG

AFM24

Tetravalent, bispecific EGFR- and CD16A-binding innate cell engager.

BIOLOGICAL

SNK01

Patient-specific ex-vivo expanded autologous natural killer cells.

Sponsors & Collaborators

  • Affimed GmbH

    collaborator INDUSTRY

  • NKGen Biotech, Inc.

    lead INDUSTRY

Principal Investigators

  • Paul Chang, MPH · NKGen Biotech, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-03
Primary Completion
2023-09-21
Completion
2023-09-21
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05099549 on ClinicalTrials.gov